SNCA and Parkinson disease: On the other hand, a human cell model showed that treatment with beta-adrenoceptor blockers (BBs) led to a significant increase in the expression of α-synuclein (SNCA) mRNA levels and elevated α­synuclein protein concentrations, which might facilitate the development of PD [9].